RecruitingPhase 3NCT03150693

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Studying Acute graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alliance for Clinical Trials in Oncology
Principal Investigator
daniel_deangelo@dfci.harvard.edu J. DeAngelo, MD, PhD
Dana-Farber Cancer Institute
Intervention
Allopurinol(drug)
Enrollment
310 enrolled
Eligibility
18-39 years · All sexes
Timeline
20172027

Study locations (30)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03150693 on ClinicalTrials.gov

Other trials for Acute graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Acute graft versus host disease

← Back to all trials